NEW YORK, January 1, 2026, 12:08 ET — Market closed.
- Johnson & Johnson shares last closed up 0.02% at $206.95 on Wednesday, a day before the New Year’s Day market holiday.
- Big Pharma came back into focus after a Reuters report said drugmakers plan 2026 list-price increases on at least 350 medicines, with a median hike of about 4%.
- J&J’s next major scheduled catalyst is its fourth-quarter earnings call on Jan. 21.
Johnson & Johnson shares were steady heading into 2026, last closing up 0.02% at $206.95 on Wednesday, with U.S. stock markets shut on Thursday for the New Year’s Day holiday.
Why it matters now: investors are starting the year with U.S. drug pricing back on the agenda after Reuters reported drugmakers plan to raise list prices on at least 350 branded medicines in 2026, even as the Trump administration presses for cuts.
For Johnson & Johnson, attention is also turning to Jan. 21, when CEO Joaquin Duato and CFO Joseph Wolk are scheduled to discuss fourth-quarter results on an investor call, the company said.
The broader market ended 2025 lower, with the S&P 500 down 0.74%, the Nasdaq off 0.76% and the Dow down 0.63% in the final session.
J&J traded between $206.42 and $207.48 in that session, with about 4.08 million shares changing hands, LSEG data showed.
The Reuters report underscored how drug pricing debate often starts with list prices — the sticker price — even though insurers and pharmacy benefit managers (PBMs), the middlemen who negotiate drug coverage, typically secure rebates and discounts that lower net prices.
“These deals … nibble around the margins,” said Dr. Benjamin Rome, a health policy researcher at Brigham and Women’s Hospital in Boston, referring to pricing agreements and discount programs that do not address the broader drivers of U.S. drug costs. Reuters
For large drugmakers such as J&J, the policy backdrop can matter as much as product news because U.S. pricing and payer negotiations help shape demand and margins across major therapies.
Litigation remains another overhang investors monitor: J&J has said it will appeal a late-December U.S. jury verdict that ordered it to pay $1.5 billion in a talc-related cancer case.
On the corporate front, the company said on Dec. 29 it completed its $3.05 billion cash acquisition of Halda Therapeutics and expects about $0.20 of dilution to adjusted earnings per share — a profit measure that excludes certain one-time items — split between 2025 and 2026.
Before the next session on Friday, investors will be watching how the healthcare sector trades as U.S. equities reopen after the holiday break.
The early-January U.S. data calendar ramps up next week, with the ISM manufacturing survey scheduled for Jan. 5 and the Labor Department’s December employment report due Jan. 9 — releases that can move interest-rate expectations and, in turn, defensive groups like healthcare.
On charts, J&J has been pinned around $207; a drop below Wednesday’s $206.42 intraday low would be an early sign that sellers are regaining control, while a move back above the $208 area would put late-December highs back in view.
The next major company catalyst is the Jan. 21 earnings call, when investors will look for 2026 signposts on demand trends across MedTech and Innovative Medicine, and any updated color on pricing pressure and litigation exposure.
